Published in Cancer Res on July 21, 2009
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol (2009) 1.46
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Oncotarget (2015) 0.84
Regulation of the DNA damage response by ubiquitin conjugation. Front Genet (2015) 0.78
Hypothesis: NDL proteins function in stress responses by regulating microtubule organization. Front Plant Sci (2015) 0.75
The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell (1999) 5.92
Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol (2005) 5.16
70-kD heat shock-related protein is one of at least two distinct cytosolic factors stimulating protein import into mitochondria. J Cell Biol (1988) 3.04
Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev Cell (2001) 3.03
Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ (2005) 3.00
The transport of proteins into the nucleus requires the 70-kilodalton heat shock protein or its cytosolic cognate. Mol Cell Biol (1992) 2.85
N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet (2000) 2.47
The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res (2003) 2.01
Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res (2000) 1.80
Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res (1998) 1.78
A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest (1997) 1.74
N-myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury. J Biol Chem (2005) 1.57
Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating and growth arrested cells. Biochim Biophys Acta (1999) 1.54
Ndrg1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves. Mol Cell Biol (2004) 1.53
NDRG1 is necessary for p53-dependent apoptosis. J Biol Chem (2004) 1.51
NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis (2007) 1.47
BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol (2007) 1.33
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. Ann N Y Acad Sci (2000) 1.31
Identification of a novel class in the alpha/beta hydrolase fold superfamily: the N-myc differentiation-related proteins. Proteins (2002) 1.25
Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol (2006) 1.12
RACK1 and CIS mediate the degradation of BimEL in cancer cells. J Biol Chem (2008) 1.05
Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein. Biochem Biophys Res Commun (2000) 1.00
Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res (2005) 1.00
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res (2005) 0.98
Cloning and characterization of TDD5, an androgen target gene that is differentially repressed by testosterone and dihydrotestosterone. Proc Natl Acad Sci U S A (1997) 0.97
High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res (2001) 0.95
The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells. FEBS Lett (1999) 0.94
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. Mol Cancer Ther (2005) 0.93
Bim, Bak, and Bax regulate osteoblast survival. J Bone Miner Res (2008) 0.92
Enhanced expression of a novel protein in human cancer cells: a potential aid to cancer diagnosis. Cell Biol Toxicol (2002) 0.92
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res (2002) 0.89
Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth Disease. Hum Mutat (2003) 0.88
Correlation of N-myc downstream-regulated gene 1 overexpression with progressive growth of colorectal neoplasm. World J Gastroenterol (2004) 0.83
Association of N-myc downregulated gene 1 with heat-shock cognate protein 70 in mast cells. Biol Pharm Bull (2004) 0.82
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther (2008) 3.07
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res (2007) 2.44
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol (2009) 2.07
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res (2011) 2.03
Induction of sarcomas by mutant IDH2. Genes Dev (2013) 2.02
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res (2009) 1.98
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol (2013) 1.94
Aurora kinases: new targets for cancer therapy. Clin Cancer Res (2006) 1.85
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res (2007) 1.79
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem (2012) 1.79
Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res (2007) 1.70
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res (2007) 1.58
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol (2005) 1.55
Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol (2004) 1.54
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol (2002) 1.50
Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest (2003) 1.49
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol (2008) 1.43
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol (2010) 1.43
Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res (2011) 1.34
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res (2013) 1.34
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer (2012) 1.25
Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res (2012) 1.20
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther (2008) 1.16
Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy (2009) 1.16
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell (2009) 1.15
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res (2008) 1.12
Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09
Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther (2013) 1.09
Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol (2011) 1.09
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci Signal (2013) 1.08
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res (2009) 1.08
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res (2006) 1.07
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res (2008) 1.07
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res (2012) 1.05
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res (2011) 1.05
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer (2005) 1.04
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One (2012) 1.03
PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res (2012) 1.00
The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent. Cell Cycle (2012) 0.99
Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine. Inorg Chem (2009) 0.99
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res (2005) 0.98
The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res (2009) 0.98
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol (2008) 0.98
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma (2013) 0.98
Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther (2013) 0.97
Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol (2011) 0.97
Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology (2012) 0.96
Treatment of metastatic esophagus and gastric cancer. Semin Oncol (2004) 0.95
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging. Clin Cancer Res (2011) 0.94
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Invest New Drugs (2010) 0.93
Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res (2015) 0.92
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther (2012) 0.92
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res (2003) 0.91
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther (2014) 0.91
Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J Clin Oncol (2011) 0.90
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology (2009) 0.90
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res (2010) 0.90
Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther (2003) 0.90
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res (2002) 0.89
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol (2008) 0.89
Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother Biol Response Modif (2003) 0.88
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol (2010) 0.88
Moving forward one Notch at a time. J Clin Oncol (2012) 0.88
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemother Pharmacol (2009) 0.87
Dramatic improvement in pulmonary hypertension with rapamycin. Chest (2010) 0.84
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma. Cancer Chemother Pharmacol (2015) 0.84
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 0.81
Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol (2013) 0.79
Using patients as their own controls for cost evaluation of phase I clinical trials. J Clin Oncol (2004) 0.79
Characterization of computed tomography scan abnormalities in patients with biopsy-proven hepatic metastases from uveal melanoma. Arch Ophthalmol (2011) 0.78
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Invest New Drugs (2002) 0.78
PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor. Anticancer Res (2013) 0.78
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res (2012) 0.77
It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol (2011) 0.77
Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother Biol Response Modif (2005) 0.77
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS. NMR Biomed (2011) 0.76
Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. Sarcoma (2010) 0.75
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest New Drugs (2012) 0.75
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am J Clin Oncol (2005) 0.75
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Res (2016) 0.75